Literature DB >> 10799917

Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant.

J T Ulrich1, W Cieplak, N J Paczkowski, S M Taylor, S D Sanderson.   

Abstract

A conformationally biased decapeptide agonist of human C5a anaphylatoxin (YSFKPMPLaR) was used as a molecular adjuvant in stimulating an Ag-specific CTL response against murine P815S target cells expressing an Ld-restricted CTL epitope of the hepatitis B surface Ag (HBsAg). Groups of BALB/c mice (H-2d) were immunized with aqueous solutions of the HBsAg CTL epitopes (IPQSLDSWWTSL and IPQSLDSWWTSLRR); the C5a agonist (YSFKPMPLaR); the C5a agonist and HBsAg CTL epitopes admixed (IPQSLDSWWTSL and IPQSLDSWWTSLRR + YSFKPMPLaR); the C5a-active, HBsAg CTL epitope-C5a agonist constructs (IPQSLDSWWTSLYSFKPMPLaR, IPQSLDSWWTSLRRYSFKPMPLaR, and IPQSLDSWWTSLRVRRYSFPMPLaR); a C5a-inactive, reverse-moiety construct (YSFKPMPLaRRRIPQSLDSWWTSL); and a C5a-attenuated, carboxyl-terminal-blocked construct (IPQSLDSWWTSLRRYSFKPMPLaRG). Ag-specific CD8+ CTL responses were observed after the secondary boost in the absence of any added adjuvant only in mice that were immunized with C5a-active contructs, IPQSLDSWWTSLRRYSFKPMPLaR and IPQSLDSWWTSLRVRRYSFKPMPLaR. These two C5a-active immunogens contained potential subtilisin-sensitive linker sequences between the HBsAg CTL epitope and the C5a agonist; i.e., a double-Arg (RR) and a furin protease sensitive sequence (RVRR). The introduction of these potentially cleavable sequences may be a method of increasing the likelihood of liberating the CTL epitope from the C5a agonist by intracellular proteases, thereby facilitating entry of the epitope into Ag-processing pathways via an exogenous route.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799917     DOI: 10.4049/jimmunol.164.10.5492

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Surface conjugation of EP67 to biodegradable nanoparticles increases the generation of long-lived mucosal and systemic memory T-cells by encapsulated protein vaccine after respiratory immunization and subsequent T-cell-mediated protection against respiratory infection.

Authors:  Shailendra B Tallapaka; Bala V K Karuturi; Pravin Yeapuri; Stephen M Curran; Yogesh A Sonawane; Joy A Phillips; D David Smith; Sam D Sanderson; Joseph A Vetro
Journal:  Int J Pharm       Date:  2019-05-08       Impact factor: 5.875

2.  Encapsulation of an EP67-Conjugated CTL Peptide Vaccine in Nanoscale Biodegradable Particles Increases the Efficacy of Respiratory Immunization and Affects the Magnitude and Memory Subsets of Vaccine-Generated Mucosal and Systemic CD8+ T Cells in a Diameter-Dependent Manner.

Authors:  Bala V K Karuturi; Shailendra B Tallapaka; Pravin Yeapuri; Stephen M Curran; Sam D Sanderson; Joseph A Vetro
Journal:  Mol Pharm       Date:  2017-04-03       Impact factor: 4.939

3.  Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses.

Authors:  D Chen; K F Weis; Q Chu; C Erickson; R Endres; C R Lively; J Osorio; L G Payne
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.

Authors:  Bala Vamsi K Karuturi; Shailendra B Tallapaka; Joy A Phillips; Sam D Sanderson; Joseph A Vetro
Journal:  Clin Immunol       Date:  2015-06-23       Impact factor: 3.969

Review 5.  Peptide-Based Vaccines for Tuberculosis.

Authors:  Wenping Gong; Chao Pan; Peng Cheng; Jie Wang; Guangyu Zhao; Xueqiong Wu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

6.  Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone.

Authors:  Joy A Phillips; Edward L Morgan; Yuxiang Dong; Garry T Cole; Cody McMahan; Chiung-Yu Hung; Sam D Sanderson
Journal:  Bioconjug Chem       Date:  2009-09-29       Impact factor: 4.774

7.  Model structures of inactive and peptide agonist bound C5aR: Insights into agonist binding, selectivity and activation.

Authors:  Soumendra Rana; Amita Rani Sahoo
Journal:  Biochem Biophys Rep       Date:  2015-03-24

8.  The effect of aqueous extract of Xinjiang Artemisia rupestris L. (an influenza virus vaccine adjuvant) on enhancing immune responses and reducing antigen dose required for immunity.

Authors:  Ailian Zhang; Danyang Wang; Jinyao Li; Feng Gao; Xucheng Fan
Journal:  PLoS One       Date:  2017-08-25       Impact factor: 3.240

9.  Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a.

Authors:  Sam D Sanderson; Marilyn L Thoman; Kornelia Kis; Elizabeth L Virts; Edgar B Herrera; Stephanie Widmann; Homero Sepulveda; Joy A Phillips
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

10.  Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice.

Authors:  Haniyeh Ghaffari-Nazari; Jalil Tavakkol-Afshari; Mahmoud Reza Jaafari; Sahar Tahaghoghi-Hajghorbani; Elham Masoumi; Seyed Amir Jalali
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.